The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness

International Ophthalmology

Volumn 36, Issue 5, 2016, Pages 665-670

  Omay, Esra ^a   Elgin, Ufuk ^a   Sen, Emine ^a   Yilmazbas, Pelin ^a  

^a Ulucanlar Eye Hospital   (Turkey)

Author keywords

Anti VEGF; Bevacizumab; Central corneal thickness; Intraocular pressure; Intravitreal injection; Ranibizumab

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL CORNEAL THICKNESS; CENTRAL SEROUS RETINOPATHY; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EYE EXAMINATION; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON CONTACT TONOMETER; PACHYMETER; PROSPECTIVE STUDY; RETINA VEIN OCCLUSION; ANTAGONISTS AND INHIBITORS; CORNEA; CORNEAL PACHYMETRY; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OCULOPLETHYSMOGRAPHY; PATHOLOGY; RETINAL DISEASES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CORNEA; CORNEAL PACHYMETRY; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANIBIZUMAB; RETINAL DISEASES; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84954459960     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-016-0171-1     Document Type: Article

References (20)

1. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS (2014) Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev 8:CD005139. doi:10.1002/14651858.CD005139.pub3
2. Yeh S, Kim SJ, Ho AC, Schoenberger SD, Bakri SJ, Ehlers JP, Thorne JE (2015) Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of ophthalmology. Ophthalmology 122:769. doi:10.1016/j.ophtha.2014.10.013
3. Küçükerdönmez C, Gelisken F, Yoeruek E, Bartz-Schmidt KU, Leitritz MA (2015) Switching intravitreal anti-VEGF treatment in neovascular age-related macular degeneration. Eur J Ophthalmol 25:51–56
4. Simó R, Sundstrom JM, Antonetti DA (2014) Ocular Anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care 37:893–899
5. Kodjikian L, Decullier E, Souied EH, Girmens JF, Durand EE, Chapuis FR, Huot L (2014) Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials. Graefes Arch Clin Exp Ophthalmol 252:1529–1537
6. Schmid MK, Bachmann LM, Fäs L, Kessels AG, Job OM, Thiel MA (2015) Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol 99:141–146
7. Shikari H, Silva PS, Sun JK (2014) Complications of intravitreal injections in patients with diabetes. Semin Ophthalmol 29:276–289
8. Van der Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS (2011) A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 31:1449–1469
9. Morshedi RG, Ricca AM, Wirostko BM (2014) Ocular hypertension following intravitreal antivascular endothelial growth factor therapy: review of the literature and possible role of nitric oxide. J Glaucoma (Epub ahead of print)
10. SooHoo JR, Seibold LK, Kahook MY (2014) The link between intravitreal antivascular endothelial growth factor injections and glaucoma. Curr Opin Ophthalmol 25:127–133
11. Abedi G, Adelman RA, Salim S (2013) Incidence and management of elevated intraocular pressure with antivascular endothelial growth factor agents. Semin Ophthalmol 28:126–130
12. Lemos-Reis R, Moreira-Gonçalves N, Melo AB, Carneiro AM, Falcão-Reis FM (2014) Immediate effect of intravitreal injection of bevacizumab on intraocular pressure. Clin Ophthalmol 23:1383–1388
13. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J (2009) Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye 23:181–185
14. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P (2009) Short-term effect of intravitreal injection of ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 18:658–661
15. Cacciamani A, Oddone F, Parravano M, Scarinci F, Di Nicola M, Lofoco G (2013) Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length. Jpn J Ophthalmol 57:63–67
16. Pérez-Rico C, Benítez-Herreros J, Castro-Rebollo M, Gómez-Sangil Y, Germain F, Montes-Mollón MA, Teus MA (2010) Effect of intravitreal ranibizumab on corneal endothelium in age-related macular degeneration. Cornea 29:849–852
17. Segal O, Ferencz JR, Cohen P, Nemet AY, Nesher R (2013) Persistent Elevation of intraocular pressure following intravitreal injection of bevacizumab. IMAJ 15:420–423
18. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM (2008) Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 246:955–958
19. Krohne TU, Eter N, Holz FG, Meyer CH (2008) Intraocularpharmacokinetics of bevacizumab after single use intravitreal injection in humans. Am J Ophthalmol 146:508–512
20. Güler M, Capkın M, Simşek A, Bilak S, Bilgin B, Hakim Reyhan A, Fırat M (2014) Short-term effects of intravitreal bevacizumab on cornea and anterior chamber. Curr Eye Res 39:989–993